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Rheumatoid arthritis is an autoimmune systemic disease characterized mainly by inflammatory 
compromise of diarthrodial joints. Multiple drug therapies have been developed to control the activity 
of rheumatoid arthritis, among them, the first line of disease-modifying antirheumatic drugs (DMARD), 
and novel drug therapies such as the anti-TNF alpha therapy, with satisfactory clinical outcomes. 
Despite this positive fact, the use of this therapy implies the risk of producing negative effects due to 
its mechanism of action, which has been associated with multiple infections, especially tuberculosis, 
making it necessary to use screen tests before resorting to this kind of drugs. 
We present the case of a 58-year-old female patient, with a six-year history of rheumatoid arthritis. 
The patient developed disseminated tuberculosis with compatible radiological and histological findings 
after receiving treatment with infliximab (anti-TNF therapy). No test was performed to screen for latent 
tuberculosis infection prior to the administration of infliximab.
The performance of routine screenings tests for tuberculosis prior to anti-TNF alpha therapy plays an 
essential role in the detection of asymptomatic patients with latent tuberculosis. This is the only way to 
identify those patients who would benefit from anti-tuberculosis drugs before the initiation of anti-TNF 
alpha therapy, which makes the difference in the search of a significant reduction in the incidence of 
tuberculosis and its associated morbidity and mortality.
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tumor necrosis factor-alpha; biological therapy; infliximab; Colombia.
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La tuberculosis en la era del tratamiento con fármacos inhibidores del factor de necrosis tumoral 
alfa: ¿por qué persiste el riesgo?
La artritis reumatoidea es una enfermedad crónica de carácter autoinmunitario caracterizada 
principalmente por el compromiso inflamatorio de las articulaciones cartilaginosas. Se han desarrollado 
múltiples tratamientos farmacológicos para controlar el avance de la artritis reumatoidea, entre ellos, los 
fármacos antirreumáticos modificadores de la enfermedad, además de nuevos esquemas terapéuticos 
con inhibidores del factor de necrosis tumoral alfa, con resultados clínicos satisfactorios. Sin embargo, 
el uso de tales medicamentos no resulta inocuo, ya que se los ha asociado con diversos efectos 
secundarios, especialmente, infecciones como la tuberculosis, lo cual exige la aplicación de pruebas 
de tamización antes de utilizarlos.
Se reporta el caso de una paciente de 58 años de edad con artritis reumatoidea de seis años de 
evolución, que después de recibir tratamiento con uno de estos fármacos, el infliximab, desarrolló 
tuberculosis diseminada, cuyo diagnóstico se confirmó mediante radiología e histopatología. No se 
emplearon pruebas de detección de la tuberculosis latente antes de prescribirle el infliximab. 
Las pruebas de tamización para tuberculosis deben emplearse de forma rutinaria, con el fin de detectar 
aquellos pacientes con tuberculosis latente, ya que es la única manera de determinar si se requiere 
profilaxis antituberculosa antes de administrar dichos fármacos, hecho que marca la diferencia cuando 
se busca disminuir la incidencia de tuberculosis y la consecuente morbimortalidad.
Palabras clave: Mycobacterium tuberculosis; tuberculosis; diagnóstico; artritis reumatoidea; factor de 
riesgo; factor de necrosis tumoral alfa; terapia biológica; infliximab; Colombia.
doi: https://doi.org/10.7705/biomedica.v38i0.3458
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Rheumatoid arthritis is a chronic, complex, and 
heterogeneous autoimmune disease. It is character-
ized by the presence of long-standing inflammation 
of the diarthrodial joints resulting in a symmetric 
polyarthritis and synovial membrane hypertrophy, 
followed by progressive joint damage, bone and 
cartilage destruction, as well as deformity (1). 
Joint damage and physical disability are the two 
major adverse outcomes of the disease reducing 
quality of life and causing premature mortality (2).
Less joint damage and better physical function 
have been unequivocally shown to be a conse-
quence of the early implementation of conventional 
synthetic disease-modifying anti-rheumatic drugs 
(csDMARD) in addition to glucocorticoids (3). 
However, some patients in therapy with csDMARD 
(even with the concomitant use of two drugs) still 
present clear signs of the disease, which has led 
to the research for novel drug therapies that would 
prevent the progression of the disease and have a 
positive impact on their quality of life. 
In the last few decades, pathophysiological path-
ways related to autoimmune diseases have shown 
that the tumor necrosis factor (TNF) is one of the 
most relevant targets for treatment and remission 
induction, thus opening the way to the develop-
ment of drugs such as adalimumab, etanercept, 
infliximab, certolizumab pegol, and golimumab, all 
of which act as TNF inhibitors (4). 
In spite of the benefits associated with these new 
drugs, the risks related to blocking the TNF pathway 
must be acknowledged. A high predisposition to cer-
tain infections, particularly tuberculosis, is one of the 
most frequent complications of such blocking (5).
We present a case of disseminated tuberculosis in 
a rheumatoid arthritis patient under anti-TNF-alpha 
therapy and discuss the topic in the light of updated 
recommendations for tuberculosis prevention when 
administering this treatment. 
Case report
A 58-year-old woman with a six-year history 
of rheumatoid arthritis was examined for a 10-
day history of headaches with 7/10 intensity and 
presence of unstable gait. Immunomodulatory 
therapy included methotrexate 10 mg/week starting 
five years before and biological therapy for the last 
year (anti-TNF-alpha therapy: infliximab, 200 mg 
every 6 weeks). Infliximab was started due to the 
failure of remission with csDMARD. 
At the moment of hospitalization, the patient did 
not present any sign of rheumatoid arthritis activity 
(Clinical Diseases Activity Index: 0). A computed 
tomography (CT) scan of the brain was done 
showing a hypodense basal right lesion asso-
ciated with vasogenic edema in the left frontal lobe 
upon which extension studies were requested. 
Brain magnetic resonance imaging showed supra- 
and infratentorial lesions highly suggestive of 
caseous granulomas (figure 1). A chest CT showed 
centrilobular micronodules with soft tissue density 
and branched centrilobular linear densities (figure 
2). Abdomino-pelvic CT showed iliac mesenteric 
and retroperitoneal lymphadenopathy and wall 
thickening of the distal ileum (figure 3), which 
is highly suggestive of tuberculosis as a first 
diagnostic possibility. Lymph node biopsy reported 
granulomatous lymphadenitis with acid-alcohol 
resistant bacilli, thus confirming the diagnosis. 
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Figure 1. A, B. Axial T2-weighted brain MRI image showing 
multiple irregular intra-axial lesions with double central hypo-
intense halo surrounded by vasogenic edema. C. Diffusion-
weighted image showing no restriction on the diffusion of water. D. 
T1-weighted image showing an irregular thick ring enhancement
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Tuberculin skin tests (TST), interferon gamma 
release assays (IGRA) or chest x-rays were not 
done to screen for latent tuberculosis infection prior 
to the administration of infliximab.
The patient was started off with the classic four-
drug regime for the empiric treatment of tubercu-
losis (rifampicin, isoniazid, ethambutol, and pyra-
zinamide), and was discharged one week after 
admission. Anti-TNF-alpha therapy administration 
was suspended and maintenance management 
with prednisolone 7.5 mg/day in addition to chloro-
quine 250 mg/day was established.
Discussion
Given that an important fraction of rheumatoid 
arthritis patients was unable to achieve remission 
on treatment with csDMARD alone, and the better 
understanding of the pathophysiological pathways 
of the disease, new drugs have been developed 
to achieve clinical remission and improve patients’ 
quality of life (6). However, these therapies are not 
100% safe and innocuous, and can have severe 
side effects that put patients’ lives at risk (7) as 
their action is not limited to blocking the abnormal 
pathways that lead to autoimmune disease develop-
ment. There is no doubt about the benefits of using 
anti-TNF agents in rheumatoid arthritis patients. 
In fact, anti-TNF-alpha therapy for rheumatoid 
arthritis is now standard care, and it typically 
follows methotrexate (MTX) in patients who are not 
doing well. In the majority of cases (70-80%), it is 
used jointly with MTX since the additional benefit of 
the combination has been demonstrated (4), i.e., 
organic chemicals of ~400 Da absorbable via the 
gut, this is no longer the case. There are now a 
plethora of important medicines which are proteins 
and injectable, which have dramatically improved 
the therapy of many inflammatory diseases and of 
cancer. Most of these are monoclonal antibodies, 
some are receptor Ig Fc fusion proteins, others are 
cytokines or enzymes. The key to this new aspect 
of therapeutics has been the filling of unmet needs, 
and the consequent commercial success, which 
promoted further research and development. The 
first ‘biologic’ for a common disease, rheumatoid 
arthritis (RA). Anti-TNF-alpha therapy also critically 
alters the regulation of inflammatory processes and 
the pathways of cell apoptosis, activation, recruit-
ment and differentiation (8).
Five anti-TNF-alpha drugs are currently in clinical 
use. They have structural differences and, thus, 
their therapeutic indications differ (6,7) (table 1).
A
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Figure 2. Abdominal CT showing wall thickening of the 
distal ileum
Figure 3. Chest CT showing centrilobular micronodules with 
apical dominance branched linear densities associated with 
“tree-in-bud” pattern
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The initiation of anti-TNF-alpha therapy is related 
to the development of multiple adverse effects 
including cardiovascular disease, malignancies and 
serious infections that may endanger the patient’s 
life (8,17,18). Among them, opportunistic infections 
are a major cause of morbidity and mortality, with 
a greater incidence of tuberculosis due to the 
pathophysiological role of TNF. In humans, TNF 
increases the phagocytic capacity of macrophages 
that ultimately go into apoptosis leading to the death 
of mycobacteria and stimulating the production of 
chemokines in the process. TNF also regulates the 
expression of adhesion molecules on endothelial 
cells which are important for recruiting mononuclear 
cells, an event that plays an important role in the 
formation of granulomas (19,20). The absence of 
TNF prevents the formation of granulomas and, 
thus, infection cannot be contained (20).
According to the evidence available, the risk of 
developing tuberculosis increases 1.6-25 times 
after the start of anti-TNF-alpha therapy depending 
on the drug used (7,21), a fact that is enhanced 
when tuberculosis incidence is very high (22).
In 1993, the World Health Organization (WHO) 
declared tuberculosis a health emergency poten-
tially affecting one third of the world’s population. 
This translates into additional costs in healthcare 
services and a negative impact on the economy. 
After AIDS, tuberculosis is currently the second-
leading cause of death worldwide among diseases 
caused by infectious agents (23). According to 
the latest WHO statistics from 2013, the annual 
incidence of tuberculosis in Colombia is 32 per 
100,000 in the general population (24). About one-
third of the world’s population is estimated to have 
latent tuberculosis infection (23,25).
The incidence of tuberculosis in patients receiving 
anti-TNF alpha drugs varies depending on the type 
of therapy, as the specific characteristics of each 
biological agent differ (26). In the case of soluble 
TNF-alpha interaction with TNF-alpha receptor 1, 
this receptor is essential for both granuloma for-
mation and containment of intracellular pathogens 
unlike membrane-bound TNF-alpha, which exerts 
its action via TNF receptor 2, and whose role is less 
significant in infection containment and formation 
of granulomas (20,27). These processes explain 
the following three key points:
• The increased risk of tuberculosis in patients 
receiving monoclonal antibodies (infliximab 
and adalimumab) vs. those patients receiving 
etanercept (28).
• The earlier appearance of tuberculosis in patients 
receiving therapy with infliximab (8,19,20)
• The use and benefits of infliximab in granu-
lomatous diseases such as Crohn’s disease and 
sarcoidosis (12,29)
Various international studies have shown the inci-
dence rate of tuberculosis in patients receiving anti-
TNF-alpha therapy (table 2), but currently there are 
no local Colombian statistics available on the risk 
of active tuberculosis in patients with rheumatic 
diseases receiving anti-TNF-alpha therapy. However, 
several pulmonary and extrapulmonary tuberculo-
sis cases in patients under anti-TNF-alpha therapy 
have been reported (34-41).
There have been multiple case reports worldwide of 
patients on biological therapy who have developed 
pulmonary and/or extrapulmonary tuberculosis 
(42,43). In a multicenter retrospective study in the 
Table 1. Anti-TNF-alpha therapy
 Anti-TNF-alpha  Mechanism of action  Clinical indications
Infliximab (9,10) A chimeric murine/human IgG1 
monoclonal antibody
Rheumatoid arthritis, psoriasis, psoriatic arthritis, 
ankylosing spondylitis, ulcerative colitis, Crohn´s 
disease and sarcoidosis
Adalimumab (11) Fully human recombinant IgG1 
constant and variable regions
Rheumatoid arthritis, psoriasis, psoriatic arthritis, 
ankylosing spondylitis, juvenile rheumatoid 
arthritis, ulcerative colitis and Crohn´s disease
Golimumab (12,13) Fully human IgG1 constant and 
variable regions
Rheumatoid arthritis, psoriatic arthritis, ankylosing 
spondylitis and ulcerative colitis
Certolizumab pegol 
(14-16)
Humanized antigen-binding fragment (FAB) 
of a monoclonal antibody attached to a 
polyethylene glycol 
Rheumatoid arthritis, psoriatic arthritis, ankylosing 
spondylitis and Crohn´s disease
Etanercept (13) Soluble TNF receptor fusion protein composed 
of two extracellular domains of human TNF-R2 
merged to the Fc fragment of human IgG1
Rheumatoid arthritis, psoriatic arthritis, psoriasis, 
juvenile rheumatoid arthritis and ankylosing 
spondylitis
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Netherlands on the importance of tuberculosis 
screening prior to the administration of biological 
therapy conducted in 611 patients with Crohn’s 
disease, 75.8% of them were screened for tubercu-
losis (TST, IGRA or chest radiography), and 3% 
were positive. Half of this group received treatment 
for latent tuberculosis infection (isoniazid), and one 
untreated patient with a positive test developed 
pulmonary tuberculosis (44).
A retrospective study in the United States found 
that 130 patients had developed tuberculosis after 
the start of therapy with infliximab. However, only 
67 of those who had started infliximab therapy in 
2001, when the FDA issued the recommendation 
of tuberculosis screening prior to anti-TNF-alpha 
therapy, were evaluated. The study showed that 
20 of the patients had not been screened for 
tuberculosis with a TST test while 23 patients had a 
chest x-ray, of whom 22 had normal results and one 
was reported as having unknown results. Among 
this group of patients, 14 developed pulmonary 
tuberculosis, five extrapulmonary tuberculosis and 
three disseminated tuberculosis (45).
The conclusion from these two studies is that some 
patients were not routinely screened for tuberculo-
sis, and others did not receive prophylactic treatment 
in spite of the fact that they had a positive screening 
result compatible with latent tuberculosis infection. 
Another remarkable conclusion is that although 
initial tests were negative, the development of active 
tuberculosis infection during the treatment should 
not have been ruled out.
Clinical presentation of tuberculosis in a patient 
under anti-TNF-alpha therapy may vary from pulmo-
nary to extrapulmonary or disseminated tuberculosis 
with an increased incidence of the latter two due 
to immunosuppression, as occurred with the case 
presented in this article (46,47).
Likewise, it is clear that the diagnosis of an autoim-
mune disease, the use of csDMARD and steroid 
therapy represent by themselves an increased 
risk of concomitant tuberculosis (5,48-50) psoriatic 
arthritis (PsA, with a relative risk of 3.68 for 
rheumatoid arthritis, 3.4 for metothrexate, 11.7 for 
leflunomide and 2,4 for corticosteroids (47).
Taking into account these statistics and the role 
of TNF in tuberculosis control, as well as the 
increased risk of tuberculosis in patients with 
autoimmune diseases, as well as the use of 
DMARD therapy, tuberculosis screening before 
starting anti-TNF-alpha therapy is essential and 
mandatory (5,8,29). Unfortunately, this was not 
observed in the case we present. 
The Centers for Disease Control and Prevention 
(CDC) recommend screening patients for Myco-
bacterium tuberculosis risk factors before initiating 
anti-TNF-alpha therapy (30) in the following cases:
• People living in a congregate setting (e.g., jail, 
homeless shelter or chronic care facility)
• TST positive >5 mm
• Substance abuse
• Health care employment in settings with tubercu-
losis patients
• Chest X-ray findings consistent with previous 
tuberculosis
We also searched for tuberculosis screening proto-
cols prior to initiating treatment with anti-TNF-alpha 
drugs (51,52), and we found that routine chest 
X-ray was a common, widespread recommendation 
in various guidelines and studies. Regarding the 
use of TST, most guidelines and protocols favor 
its widespread use with the exception of the Swiss 
guidelines (52). German guidelines propose that 
a TST be done only if discrepancy exists between 
strong epidemiological evidence of prior tuberculo-
sis exposure and negative IGRA (53). UK guidelines 
do not recommend TST for immunosuppressed 
patients (51) and the European guidelines establish 
that a TST be done on individuals without a history 
of BCG vaccination (12).
Table 2. Tuberculosis in patients treated with anti-TNF-alpha therapy
Country Tuberculosis in the 
general population
Adalimumab Etanercept Infliximab
USA (30)
Spain (31)
France (32)
Portugal (33)
6.2/100.000
21/100.000
10/100.000
33.74/100.000
IR: 176/100.000
IR: 215/100.000
4 cases/171 patients
IR: 35/100.000
IR: 114/100.000
IR: 9.3/100.000
1 case/333 patients
IR: 144/100.000
IR: 383/100.000
IR: 187.5/100.000
8 cases/456 patients
IR: incidence rate
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Regarding TST positivity, three study groups con-
sidered a result of >5 mm to be positive (31,33,53).
The French guidelines considered a >10 mm (33) 
result to be positive, while in the UK, the positivity 
corresponds to 5 mm in unvaccinated patients and 
15 mm in vaccinated patients (52). In the USA, a 
result of more than 5 mm is considered positive if 
the patient is immunosuppressed, more than 10 
mm is positive for patients in certain risk groups, 
and 15 mm if the patient is at low risk (46)
Due to the presence of false positives when 
screening with TST among individuals with prior 
exposure to BCG vaccine (54), more reliable diag-
nostic tools have been developed in recent years. 
One of the most widely used nowadays in some 
settings are the IGRA, which have better sensitivity 
than TST in immunocompromised subjects, as well 
as higher specificity. IGRA also have the advantage 
of not being influenced by prior vaccination with 
BCG or contact with nontuberculous mycobacteria 
(8,52,54,55).
The IGRA quantify interferon-gamma production 
from T cells and are based on the principle that T 
cells already sensitized to tuberculosis antigens 
produce high IFN-γ levels when they are exposed 
again. As a consequence, IGRA can improve latent 
tuberculosis infection detection specificity in BCG-
vaccinated populations (55). This testing method had 
been adopted as evidence in tuberculosis screening 
in only three of seven guidelines consulted (12, 
19,52,53). Despite the evidence on the use of 
IGRA shown in some studies, some research has 
demonstrated that TST and IGRA responses vary 
substantially among different groups of immuno-
compromised patients, and are poor predictors of 
the development of tuberculosis in them (56).
Regarding the treatment for latent tuberculosis 
infection or active tuberculosis, each consensus 
suggests a specific type of regimen, differing in 
the drugs used and the duration of treatment. The 
different treatment protocols are summarized in 
table 3. 
The clinical guidelines for the management of 
patients with rheumatoid arthritis in Colombia 
were issued in 2014 (57), and they do not include 
a screening protocol for active tuberculosis nor 
latent tuberculosis infection despite the high 
incidence of tuberculosis in the country. Neverthe-
less, the guidelines recommend ruling out latent 
or active tuberculosis in patients under treat-
ment with conventional or biologic DMARD as 
a good clinical practice. It is of great importance 
to develop recommendations on this topic and 
to encourage further local studies to evaluate 
the most appropriate treatment in cases of latent 
tuberculosis infection and active tuberculosis when 
anti-TNF-alpha therapy is required. As shown in 
table 3, there is no international consensus, and 
proposed therapies are tailored to the characteris-
tics of each country. 
It is necessary to adopt a strict and well-established 
public health policy in Colombia to enable a 
decrease in tuberculosis incidence among patients 
receiving biological therapy. This is the only possi-
ble way to reduce tuberculosis-associated morbidity 
and mortality.
The use of anti-TNF-alpha therapy has shown that 
disease progression in rheumatoid arthritis can be 
reduced satisfactorily, but it is essential to carry 
out suitable screening prior to its administration. 
Patients should also be monitored for any respiratory 
symptoms and, if found, clinicians should suspect 
the presence of pulmonary tuberculosis, especially 
in cases where clinical, laboratory, and image fin-
dings allow for a wide range of different diagnoses. 
However, even if proper screening is done prior 
to the start of anti-TNF-alpha therapy, the risk of 
tuberculosis remains, including cases with prior 
normal chest X-ray and negative TST (58-60). 
In this sense, some groups have suggested the 
use of new screening tests after the start of anti-
TNF-alpha therapy (28,45,60). Some institutions 
are adopting protocols that promote the periodic 
search for tuberculosis in patients under biological 
therapy, as proposed by Tae Sun, et al. (25), who 
did tuberculosis screening three, six and nine 
months after the start of anti-TNF-alpha therapy, 
and annually after that. Other authors recommend 
tuberculosis screening every year (12,61,62).
To achieve a significant reduction in morbidity 
and mortality, which ultimately would improve the 
patient’s quality of life, clinicians need to be very 
meticulous in the search for risk factors increasing 
the incidence of infectious diseases, and decide 
which screening test is most suitable for each 
individual patient (5,8). Lastly, patients’ safety and 
quality of life should be the main objectives of every 
rheumatologic treatment. 
In conclusion, patients with autoimmune or auto-
inflammatory diseases that benefit from anti- 
TNF-alpha therapy should be screened for infec-
tious agents, especially tuberculosis. Different tests 
have been developed to detect latent tuberculosis 
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infection (PPD, IGRA and chest radiography), as 
its proper and timely detection is key to preventing 
morbidity and mortality in patients with anti-TNF-
alpha therapy, given that these drugs mechanism 
of action decreases the immune system ability 
to form the tuberculosis granuloma. This inter-
ference with the granulomatous immune response 
increases the risk and predisposes patients to 
pulmonary, extrapulmonary or disseminated tuber-
culosis in the context of immunosuppression, with 
its subsequent complications, such as in the case 
reported here. Likewise, it is essential to establish 
internal and national guidelines to clearly define 
all the parameters and periodicity of tuberculosis 
screening once the anti-TNF-alpha is introduced.
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